石药集团出海加速:乳腺癌治疗新药获准在美开展临床

财中社
Mar 03

  3月2日,石药集团(01093)发布公告,宣布其开发的注射用紫杉醇白蛋白纳米粒(速溶型)(SYHX2011G1)已获得美国食品药品监督管理局(FDA)批准,可以在美国开展临床试验。该产品针对乳腺癌患者,特别是那些在联合化疗中失败或在辅助化疗后6个月内复发的患者,具有重要的临床适应症。

  紫杉烷类药物是治疗晚期乳腺癌的常用且有效的化疗药物,石药集团此次获批的产品采用了专利技术,旨在成为全球首个速溶白蛋白结合型紫杉醇制剂。此次临床试验的批准将进一步丰富公司的国际产品管线,提升公司的国际竞争力。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10